The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Table 1 Clinicopathologic variables and the expression of PARP1, γH2AX, BRCA1, and BRCA2 in 35 osteosarcomas

Characteristics		No.	PARP1	P	γH2AX	P	BRCA1	P	BRCA2	P
Characteristics		No.	positive	P	positive	P	positive	P	positive	P
Age, yr	< 30	24	16 (67%)	0.128	13 (54%)	0.599	10 (42%)	0.227	11 (46%)	0.983
Age, yr	≥ 30	11	10 (91%)		7 (64%)		7 (64%)		5 (45%)
Sex	female	10	5 (50%)	0.038	5 (50%)	0.589	3 (30%)	0.164	1 (10%)	0.007
Sex	male	25	21 (84%)		15 (60%)		14 (56%)		15 (60%)
Tumor size, cm	≤ 8	18	12 (67%)	0.289	10 (56%)	0.845	7 (39%)	0.238	6 (33%)	0.130
Tumor size, cm	> 8	17	14 (82%)		10 (59%)		10 (59%)		10 (59%)
Stage	I	11	5 (45%)	0.024	3 (27%)	0.046	3 (27%)	0.232	1 (9%)	0.002
	II	19	16 (84%)		14 (74%)		11 (58%)		10 (53%)
	III-IV	5	5 (100%)		3 (60%)		3 (60%)		5 (100%)
Distant metastasis	absence	30	21 (70%)	0.155	17 (57%)	0.889	14 (47%)	0.581	11 (37%)	0.008
Distant metastasis	presence	5	5 (100%)		3 (60%)		3 (60%)		5 (100%)
Latent distant metastasis	absence	25	17 (68%)	0.179	11 (44%)	0.013	9 (36%)	0.019	10 (40%)	0.283
Latent distant metastasis	presence	10	9 (90%)		9 (90%)		8 (80%)		6 (60%)
Histological grade	low	11	5 (45%)	0.008	3 (27%)	0.016	3 (27%)	0.088	1 (9%)	0.003
Histological grade	high	24	21 (88%)		17 (71%)		14 (58%)		15 (63%)
Histologic type	conventional	31	24 (77%)	0.238	19 (61%)	0.167	16 (52%)	0.316	16 (52%)	0.051
Histologic type	non-conventional	4	2 (50%)		1 (25%)		1 (25%)
BRCA2	negative	19	10 (53%)	0.001	7 (37%)	0.008	7 (37%)	0.13
BRCA2	positive	16	16 (100%)		13 (81%)		10 (63%)
BRCA1	negative	18	10 (56%)	0.009	7 (39%)	0.025
BRCA1	positive	17	16 (94%)		13 (76%)
γH2AX	negative	15	7 (47%)	0.001
γH2AX	positive	20	19 (95%)

ISSN: 1756-9966